How can #ESMOMCBS guide reimbursement & equity in cancer care?
Follow the #ESMO25 session: “ESMO-MCBS: From evidence to reimbursement”
🔗 https://ow.ly/IWG050XaWh7

The #ESMOMCBS Scorecards based on ESMO-MCBS v2.0, offer an updated resource to clinicians to aid their value-based decision-making about #CancerMedicines and improve #PatientOutcomes.
🔗 ow.ly/CEY850WBXhR

How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter.
🔗 ow.ly/8aJt50WBROf

Released on the wave of #ClinicalTrialsDay, ESMO-MCBS v 2.0 reinforces the role of research in improving #CancerCare.

🔗 Learn more: ow.ly/W2WE50VXy98

#ESMOMCBS

As the #oncology field evolves, ESMO is keeping pace - regularly ensuring its tools reflect the latest in #ClinicalEvidence and regulatory shifts. An important evolution is just around the corner — keep an eye out.
#ESMOMCBS